Showing results (121-130 of 259) with videos related to

Sort By:
Pageof 26
European Journal of Cancer (Oxford, England : 1990)|July 2, 2002
The cellular pharmacology of oxaliplatin resistanceM Mishima, G Samimi, A Kondo, et al.
Cancer Research|December 15, 1994
Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell lineP Naredi, D D Heath, R E Enns, et al.
Cancer Treatment Reports|September 1, 1982
High-dose allopurinol modulation of 5-FU toxicity: phase I trial of an outpatient dose scheduleT N Campbell, S B Howell, C Pfeifle, et al.
Molecular Pharmacology|November 28, 2001
Identification of genes that mediate sensitivity to cisplatinH Niedner, R Christen, X Lin, et al.
The Journal of Clinical Investigation|March 1, 1995
Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cellsP Naredi, D D Heath, R E Enns, et al.
Cancer Drug Delivery|January 1, 1985
Maintenance of peritoneal catheter function by the intraperitoneal administration of 32% dextran 70C E Pfeifle, S B Howell, I S Abramson, et al.
Molecular Pharmacology|January 1, 1997
Role of determinants of cadmium sensitivity in the tolerance of Schizosaccharomyces pombe to cisplatinP Perego, J Vande Weghe, D W Ow, et al.
Cancer Research|March 1, 1980
Antitumor activity of L-canavanine against L1210 murine leukemiaM H Green, T L Brooks, J Mendelsohn, et al.
Molecular Pharmacology|November 28, 2000
p53 interacts with the DNA mismatch repair system to modulate the cytotoxicity and mutagenicity of hydrogen peroxideX Lin, K Ramamurthi, M Mishima, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Enhancement of the cytotoxicity of cisplatin by the cholecystokinin antagonist MK-329 in a human pancreatic cancer cell lineR Jamshidipour, E B Pinho, D K Hom, et al.
Pageof 26